The following studies are active. Use the links in the box on the left for information on each of the active studies being conducted by PASA.
AS140026-A5 Lori Davis, M.D. and Ismene Petrakis, M.D.
Study Type: Phase II Randomized Controlled Trial (RCT)
Protocol: Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD
Participating Site: Tuscaloosa Research & Education Advancement Corporation (TREAC)/Tuscaloosa VA Medical Center (TVAMC) (Satellite site at Birmingham VA), Connecticut Research & Education Foundation (CREEF) / VA Connecticut Healthcare System (VACT), and Wayne State University, Ann Arbor VA, Detroit VA
AS170014-A6 Christopher Verrico, Ph.D.
Study Type: Phase II Clinical Trial
Protocol: Lofexidine Combined with Buprenorphine for Reducing Symptoms of Post-Traumatic Stress Disorder and Opioid Use Relapse in Veterans
Participating Site: Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)
AS140026-A3c Christopher Verrico, Ph.D. and Dewleen Baker, M.D.
Study Type: Phase I Pharmacokinetic Study
Protocol: Effects of Ethanol (EtOH) on the Pharmacokinetics of PT-150 (Formerly ORG34517)
Participating Site: Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)
Study Type: Preclinical Study
Protocol: Preclinical testing of FKBP5 Inhibitors for alcohol use disorder-PTSD comorbidity
Participating Site: The Scripps Research Institute (TSRI)
Study Type: Phase phase 1, double-blind, placebo-controlled, within subjects
Protocol: Effect of Sublingual formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers with PTSD – Alcohol Interaction Study
Participating Site: VA Connecticut Healthcare System
Study Type: In Silico Study
Protocol: Leveraging multi-omic data integration for in silico compound prioritization
Participating Site: RTI GenOmics, Bioinformatics, and Translational Research Center (GOBOT)
Study Type: Preclinical Study
Protocol: Development of a fentanyl vaccine to treat opioid use disorder
Participating Site: University of Houston